BLGOOTCChemicals & Allied ProductsFiscal year ends December 31
BIOLARGO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.07+0.00 (+0.90%)
Close on Oct 19, 2026
- Market cap
- $23.27M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
43.9%−6.6 pts over 5 years
Operating margin
-191.3%+120.5 pts over 5 years
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -56.3% | +9.7% | +26.1% | +50.8% | |
| Gross profit | -56.6% | +6.0% | +22.6% | +48.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 1.75 | 0.42 | 1.01 | |
| Debt to equity | -4.38 | 0.44 | – | |
| Net debt to EBITDA | -0.79× | -0.13× | – | |
| Interest coverage | -1.6× | -3.9× | -27.5× | |
| Inventory turnover | 2.9× | 8.2× | 13.6× | |
| Diluted shares | 88M | 196M | 307M |
Cash use needs five years of cash flow figures
Biolargo does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$8.30M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$8.30M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.70 → 1.01
- No dilutionShare count did not rise298M → 307M
- Gross margin improvedGross margin up on the prior year44.17% → 43.86%
- More efficientAsset turnover rose2.17 → 0.74